News
Click here for news in Danish.
December 13, 2013 | Company Announcements
Bavarian Nordic Introduces Incentive Program and Issues WarrantsNovember 26, 2013 | Company Announcements
Bavarian Nordic A/S – Major Shareholder AnnouncementNovember 22, 2013 | Company Announcements
Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine November 15, 2013 | Press Releases
Bavarian Nordic Completes Delivery of 20 Million Doses of IMVAMUNE® Smallpox Vaccine to the U.S. Strategic National StockpileNovember 14, 2013 | Company Announcements
Bavarian Nordic Reports Change in the Board of DirectorsNovember 14, 2013 | Company Announcements
Bavarian Nordic – Interim Financial Report for the Period 1 January to 30 September 2013 September 23, 2013 | Company Announcements
Bavarian Nordic issues Financial Calendar for 2014 August 22, 2013 | Company Announcements
Bavarian Nordic Issues WarrantsAugust 22, 2013 | Company Announcements
Bavarian Nordic Reports Financial Results for the First Half of 2013August 07, 2013 | Company Announcements
Bavarian Nordic Receives European Marketing Authorization for IMVANEX Smallpox VaccineJuly 01, 2013 | Press Releases
Bavarian Nordic CEO Anders Hedegaard Elected as Co-Chair of the Alliance for BiosecurityMay 31, 2013 | Company Announcements
Bavarian Nordic’s IMVANEX® Smallpox Vaccine Receives Positive Opinion from European Regulatory AuthoritiesMay 29, 2013 | Company Announcements
Bavarian Nordic Establishes a Sponsored Level 1 ADR Program in the USMay 29, 2013 | Company Announcements
Bavarian Nordic’s CV-301 Cancer Immunotherapy Candidate Shows Promise in Colorectal CancerMay 27, 2013 | Press Releases
Bavarian Nordic Announces Presentation of PROSTVAC® at the 2013 ASCO Annual MeetingMay 16, 2013 | Company Announcements
Bavarian Nordic – Interim Financial Report for the Period 1 January to 31 March 2013April 24, 2013 | Company Announcements
Bavarian Nordic A/S – Major Shareholder AnnouncementApril 17, 2013 | Company Announcements
Bavarian Nordic A/S – Report on the Results of the Annual General Meeting, held 17 April 2013April 16, 2013 | Company Announcements
Bavarian Nordic Receives Contract Valued up to USD 228 Million from the U.S. Government Securing Continued Production and Deliveries of IMVAMUNE® Smallpox VaccineApril 08, 2013 | Company Announcements
Bavarian Nordic Agrees on Interim Analysis with the FDA and Provides an Update on its PROSPECT Phase 3 TrialMarch 19, 2013 | Company Announcements
Bavarian Nordic A/S – Notice Convening Ordinary General MeetingMarch 12, 2013 | Company Announcements
Bavarian Nordic Announces 2012 Full Year ResultsMarch 05, 2013 | Press Releases
Bavarian Nordic Applauds Reauthorization of Key U.S. Biodefense ProgramsFebruary 13, 2013 | Company Announcements
Bavarian Nordic Presents New Clinical Data on PROSTVAC® at the 2013 Genitourinary Cancers SymposiumFebruary 12, 2013 | Company Announcements
Bavarian Nordic Awards Warrants to Newly Appointed Member of the Executive Management